Invest in Cannaray CBD

Selection of CBD Products by Cannaray CBD

Cannaray Limited is a leading European cannabis group of companies spanning both Medical Cannabis and CBD wellness brands.

Interested in Becoming an Investor?

We'd love to hear from you. Please send us an email providing details of:

  • Your full name
  • Your desired level of investment
  • Your job title and workplace (if enquiring on behalf of an organisation)
  • Your location (city, country)
  • A short intro on why you would be a good investor for Cannaray

Our Vision

Cannaray Limited's vision is to become the leading European cannabis company by 2024.

CBD leaf in the sun

Wellness CBD

Cannaray CBD is the group’s flagship CBD wellness brand – founded to make CBD easy and accessible for millions of new people. Our product range includes CBD Oil Drops for day and night, Capsules, Gummies and Muscle Balm. All Cannaray CBD products are formulated to be effective and enjoyable to use, lab-tested for purity, and are packaged in the modern, bright, and optimistic Cannaray brand colours.

Medical Cannabis

Therismos is the group's medical division, which imports and distributes cannabis-based products for medical use (CBPM) across Europe. We strive to be the leading European full-service provider of medicinal cannabis through our innovative product solutions, valuable partnerships with strategic allies, and collaboration with world-class scientists and medical practitioners.

We put patients at the heart of everything we do and aspire to improve their quality of life by offering access to the largest range and delivery routes of safe, reliable and high-quality CBPM, while ensuring medical practitioners have everything they need to fully support cannabis patients wherever they may be.

Our Practices

The Cannaray Group was founded to make the health and wellbeing properties of cannabinoids accessible to millions more people across Europe.

We have robust ESG processes in place to ensure we operate thoughtfully, responsibly and sustainably across each of our companies, with a commitment to the highest governance standards.

Men high fiving on beach

Supporting CBPM Access for All

Until CBPM becomes fully reimbursed by governments, we recognise that many prospective patients are unable to access private funded prescriptions.

We are proud to support a programme of prescription cost assistance for patients in financial need.

Read Jorja's story.

Safe and Efficient Drug Supply

Therismos' supply chain expertise in controlled, rare and orphan drugs helps large biopharma companies to deliver to patients quickly and safely.

Highest Quality Standards

We have an in-house Quality Management team across our Medical Cannabis and CBD divisions to ensure our products meet consistently high standards. Our CBPM medicines are manufactured to EU Good Manufacturing Practice (EU-GMP) standards.

Cannaray Wellness CBD is independently lab tested for purity, with full tranparency of our lab reports and certificates of analysis published on the website.

All Cannaray CBD ingestible products are fully compliant with the FSA Novel Food process and are validated on the FSA public list.

CBD extraction process

Eco-Kind Packaging

Every bottle and jar that holds Cannaray CBD's oils, capsules and topicals is made from recyclable glass. We use minimal plastic for our pumps and lids – and what we do use is 100% recyclable. Additionally, all Cannaray CBD packaging and ecommerce boxes are fully recyclable.

Expert Corporate Governance

Cannaray Limited was established with the highest standards of corporate governance, including highly experienced directors and robust financial controls

Our Scientific Advisory Board have world-class expertise across CBPM, Pain, Anxiety and Drug Delivery.

Responsible Marketing

We are committed to responsible marketing and abiding by all industry marketing and advertising codes.

sun shining through wheat field

Our People

Cannaray’s team brings a new level of professionalism to the cannabis industry with expertise covering IPOs, building companies through consolidation, life sciences, media, consumer and retail, all complementary backgrounds to create tangible shareholder value in medical cannabis and retail CBD.

Scott Maguire CEO of Cannaray CBD

Scott Maguire

Chief Executive Officer

Expertise in starting and building businesses. Scott has played a key role as an executive in building five companies or divisions of larger companies from concept to high value including trade sales and IPO. Scott has built a company from two patents to a NASDAQ listing (ticker: XBIO) and has also built a dialysis clinic chain from scratch to the UK’s second-largest private provider of dialysis services. He has assisted in building National Medical Care’s fledging international business from $15M to $350M in revenues. Scott also built a healthcare corporate finance practice from scratch to 35 professionals globally.

Andrew Garden Cannaray CBD Chairman

Andrew Garden


Highly experienced FMCG expert and successful chairman, Andrew brings over 30 years of industry experience from previous Directorship and VP roles at P&G. With a successful track record in Sales and Marketing for Health and Beauty, Andrew was appointed as Chairman in 2022. Additional specialist areas include global market knowledge and new geography expansion, strategic account management with retail and pharmacy, and global sales and marketing strategies.

David Hogg CFO Cannaray CBD

David Hogg

Chief Financial Officer

Experienced CFO, qualified Chartered Accountant and board-level director with a demonstrated history of developing and growing service businesses leading to improved shareholder value. Numerous M&A activities including the successful exit of a private equity-owned business. Developed significant improvements in management reporting, controls and strong financial reporting acting as a business partner for the development of the organisations. Lead several refinancings with strong banking relationship experience.

Josh Roberts Chief Business Officer Cannaray CBD

Joshua Roberts

Chief Business Officer

Investor and entrepreneur with experience in institutional investment and trading, international real estate investment, and private market investment. Joshua worked for Highbridge Capital Management for over a decade in London and New York and established the European trading desk for the StatArb team in London. He started angel investing in 2010 and cannabis has been his investment focus since early 2017 in both the public and private markets.

Tim Clarke CMO Cannaray CBD

Tim Clarke

Chief Marketing Officer

Experienced CMO with successful track record of building premium brands within major FMCG organisations, including Reckitt Benckiser, Bacardi and innocent drinks. Sectors include OTC Healthcare, Premium Alcoholic Spirits, Soft drinks, Laundry Care and Personal Care. Skilled at the full marketing mix including brand building, innovation, advertising and media, digital and social. Geographic experience includes global leadership roles and local assignments based in Europe, Middle East & Africa and China.

Christian Naumann Therismos MD Germany Cannaray

Christian Naumann

Managing Director, Germany

Christian looks back on a long-standing international career with blue chip pharmaceutical corporations including Schering, Bayer, WBA and Sandoz/Novartis. In his several roles in Germany, Mexico, London and Munich, he launched Rituximab’s, Enbrel’s, Humira’s & Neulasta’s biosimilars in Europe and the US for Sandoz International, expanded and optimized WBA’s private label portfolios Almus & Alvita across Europe and into new markets, launched J&J’s/Bayer’s biggest blockbuster Xarelto® (rivaroxaban) globally and lead Bayer's portfolios in General Medicine, Women’s Healthcare and Cardiology in Europe and Canada, before advising Cannabis companies and joining Therismos.

Our Non-Executive Board of Directors

Strengthening Cannaray’s offering is a world-class Board of Directors covering industry-specific expertise in listing and running public companies, life sciences, financial, legal, media and the cannabis industry.

Chris Sullivan, Ex Deputy Group CEO of RBS and Ex CEO Corporate Banking of Santander

Sir Nigel Knowles, Ex Global Co-Chairman of DLA Piper and now Chairman of DWF Group PLC

Michael Freedman, CEO of Alchemy Media and an entrepreneur in the USA cannabis sector

Group of science equipment

Our Scientific Advisory Board

The SAB is comprised of key opinion leaders covering the four approved indications to treat with medical cannabis in the UK (chemotherapy-induced nausea and vomiting, epilepsy, multiple sclerosis, chronic pain).

Gregor Zorn, Cannaray's Chief Science Officer
Professor of Cannabis Studies

Dr Daniela Tonucci, Pain Specialist

Dr Andrew Aswani, Anesthesiologist

Dr Balu Pitchiah, Consultant Psychiatrist

Dr Deane Halfpenny, Pain Specialist

Dr David Moorhouse, General Neurologist

Dr Benjamin Thomas, Pain Specialist

Dr Peter Laing, Drug Delivery Specialist

Investor News

We’re delighted to announce that our medical cannabis division Therismos GmbH has signed a multi-year contract with Alliance Healthcare Deutschland GmbH, a division of Walgreens Boots Alliance, Inc (WBA).   


The strategic partnership takes Cannaray Limited one step closer to becoming Europe’s leading cannabis company across both our medical cannabis and CBD wellness brands.

The partnership is a true collaboration, where Therismos will supply high-quality medical cannabis products to pharmacies in Germany via Alliance Healthcare Deutschland and GEHE Pharma Handel. Additionally, our German team will conduct an exclusive training programme for Alphega and gesund leben pharmacists to support them in becoming medical cannabis experts. 

We’re so happy to be joining the cooperation family of Alphega and gesund leben and bringing our quality medical cannabis products into the German market, which are available from today. 

For more information, please speak to us at

Cannaray Limited, the European Medical Cannabis and Retail CBD company, today Monday 4th April 2022, announced the completion of a £10m funding round. Participants in the round include Channel 4 Ventures, the UK’s largest media-for-equity fund, Three Bridges Private Capital, Alpha Blue Ocean and a mix of new and follow-on private investors.

Cannaray will use the majority of funds to build its Pan-European medical cannabis business. The activation for 2022 will focus on Germany and the UK, led by its teams in Berlin and London.


The media-for-equity investment by Channel 4 Ventures also gives Cannaray CBD, the company’s flagship wellness CBD brand, access to a high-reach upmarket TV audience in the UK. In Summer 2021, Cannaray launched the UK’s first major brand campaign for CBD on TV. The campaign features Cannaray’s brand ambassador and TV presenter Claudia Winkleman as she leads the charge to recruit new customers to the brand. In addition to a high-performing DTC site,, the brand is also stocked on Amazon and in over 1500 retail outlets across the UK including Tesco, Superdrug, ASDA, Waitrose and Harrods.


Scott Maguire, Cannaray Limited CEO, said: “I am delighted with the high participation of both existing and new investors within this funding round and thank them for putting their money and faith in us. The Channel 4 Ventures backing is one of the first of its kind in the European cannabis sector, and a sign of the credibility and growth opportunity available within the market. Having created one of the leading CBD brands in the UK, we are now focused on building Europe’s leading medical cannabis company and improving the lives of millions of people.” 


Vinay Solanki, Head of Channel 4 Ventures, said: “We’ve been impressed with the leadership team at Cannaray and their progress in building a portfolio spanning European Medical Cannabis and the Cannaray CBD wellness brand. This investment fits well with our strategy to back bold categories as part nof our Future4 strategy to diversify new revenue streams. We’re looking forward to supporting Cannaray’s CBD wellness brand campaign across our marketing platform and hope it drives the significant brand awareness only possible through the scale and reach of TV advertising.

Read the full interview in the Financial Times.